One customer — 12% of receivables (As of September 30, 2026)
“As of September 30, 2026, one customer represented approximately 12% of our consolidated accounts receivable.”
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Zimmer Biomet Holdings, Inc. issued €500.0 million of 4.375% notes due 2033 and $500.0 million of 5.850% notes due 2036 on November 12, 2026.
Zimmer Biomet reported three-month net sales growth of 3.1% and nine-month growth of 5.7%. Nine-month net earnings reached $628.1 million, while three-month net earnings fell to $191.6 million from $230.9 million.
Zimmer Biomet Holdings, Inc. reported third-quarter net sales of $2.063 billion, up 3.7% on a constant currency basis, and raised 2026 organic constant-currency revenue growth guidance to 3.0% - 3.5%. Adjusted diluted EPS was $1.90, consistent with the prior year period.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Zimmer Biomet raised full-year 2026 organic constant currency revenue guidance to 2.25%-3.25% (from 1%-3%) and adjusted EPS guidance to $8.47-$8.59 (from $8.40-$8.55), and increased its 2026 share repurchase plan by $250 million to up to $1 billion, following Q2 organic constant currency revenue growth of 4.0%, Hips up 5.1% and Technology & Data up 21.5%, though adjusted operating margin contracted 210 bps year-over-year to 25.7%.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted effective tax rate non-GAAP | 18% | Six Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Effective tax rate $21.8
+$1.6 Tax effect of adjustments made to earnings before taxes
-$5.4 Other certain tax adjustments
= Adjusted effective tax rate $18
|
|||
| Adjusted gross margin non-GAAP | 72% | Six Months Ended June 30, 2026 | — |
| Adjusted operating profit margin non-GAAP | 26.5% | Six Months Ended June 30, 2026 | — |
| Free cash flow non-GAAP | $554.1M | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ZBH
this stock
Zimmer Biomet Holdings, Inc.
|
$19.53B | +14.8% | +7.2% | 26.1 | 4.1% |
|
ABT
Abbott Laboratories
|
$187.95B | -13.4% | +5.7% | 40.5 | 1.1% |
|
MDT
Medtronic plc
|
$131.57B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$117.88B | -11.9% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$64.27B | -53.5% | +12.5% | 18.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Zimmer Biomet Holdings, Inc. issued €500.0 million of 4.375% notes due 2033 and $500.0 million of 5.850% notes due 2036 on November 12, 2026.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ZBH | -2.3% | +8.7% | +22.3% | +9.2% | +14.8% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -4.8% | +9.8% | +21.8% | +9.4% | +4.2% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
